Welcome to our dedicated page for Compugen SEC filings (Ticker: CGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Compugen Ltd. files foreign-issuer reports that document its clinical-stage cancer immunotherapy business, financial results and material corporate developments. Its Form 6-K filings cover quarterly and annual results, interim consolidated financial statements, management discussion and analysis, Inline XBRL financial data, and corporate updates related to programs such as COM701, COM902, rilvegostomig and GS-0321.
The filing record also documents licensing and royalty arrangements, including amendments to the AstraZeneca rilvegostomig agreement, as well as proxy materials, annual general meeting voting results, board composition and registration-statement incorporation matters under Form F-3. These disclosures frame Compugen's capital resources, collaboration economics, governance actions, clinical-development disclosures and foreign private issuer reporting obligations.
Compugen Ltd. files a shelf registration to offer up to $400,000,000 of securities, including a sales agreement allowing up to $100,000,000 of ordinary shares to be sold under an at-the-market sales agreement with Leerink Partners LLC. The base prospectus covers ordinary shares, debt securities, rights, warrants and units in one or more offerings from time to time after effectiveness. The prospectus notes our ordinary shares trade on Nasdaq and the Tel Aviv Stock Exchange (symbol CGEN) and discloses a closing sale price of $3.03 (Nasdaq) and NIS 8.361 ($2.88 equivalent) on May 14, 2026. The prospectus also summarizes business operations, clinical programs and a March 31, 2026 capitalization table that shows cash and investments and issued ordinary shares.
Compugen Ltd. reported first quarter 2026 results, highlighting steady clinical progress and a solid balance sheet. Revenue was $2.2 million, slightly below the prior year, mainly from recognition of upfront and milestone payments under its Gilead license agreement.
The company recorded a net loss of $7.7 million, or $0.08 per share, similar to the prior-year loss, as increased R&D spending of $6.9 million supported its MAIA-ovarian trial and other programs. General and administrative expenses were stable at $2.3 million.
Compugen ended March 31, 2026 with $134.9 million in cash, cash equivalents, short-term deposits and marketable securities and reported no debt, stating this cash is expected to fund operations into 2029. Management emphasized progress in its immuno-oncology pipeline and noted up to $1 billion in potential milestones plus royalties from partnerships with AstraZeneca and Gilead.
Compugen Ltd SVP of Business Development Zurit Levine exercised options and sold shares in a pre-planned transaction. On April 24, 2026, she exercised 2,000 share options at $1.15 per share and sold 2,000 ordinary shares at $3.20 per share in an open-market sale pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2025. Following these transactions, she directly held 29,375 ordinary shares.
Compugen Ltd President and CEO Ophir Eran reported an exercise-and-sale transaction in the company’s Ordinary Shares. On April 24, 2026, he exercised options to acquire 5,000 shares at an exercise price of $0.8292 per share and sold 5,000 shares in open-market trades at a weighted average price of $3.2001 per share. Following these transactions, he directly holds 11,375 Ordinary Shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 26, 2025.
Ophir Eran submitted a Form 144 notice indicating proposed sales of 5,000 ordinary shares under an Employee Stock Option Plan with cash upon exercise as the consideration method. The filing also lists recent sales of 5,625 shares on 04/01/2026 and 5,000 shares on 04/14/2026.
CGEN affiliate files a Form 144 reporting proposed and recent share sales. The filing lists 4,000 Ordinary shares to be sold under an Employee Stock Options plan with cash upon exercise. The filing also reports multiple sales by Levine Zurit totaling reported disposals across March–April 2026, each showing share counts and gross proceeds.
Compugen Ltd President and CEO Ophir Eran exercised options to acquire 5,000 ordinary shares at an exercise price of $0.8292 per share, then sold 5,000 shares in an open-market transaction at a weighted average price of $2.9042.
The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on December 26, 2025. Following these transactions, Eran directly owns 11,375 ordinary shares. The exercised option was from a grant that vested over time through quarterly installments.
Compugen Ltd SVP of Business Development Zurit Levine exercised stock options and sold a small portion of shares. On April 14, 2026, she exercised options for 2,000 Ordinary Shares at $1.15 per share and sold 2,000 Ordinary Shares at $2.80 per share in an open-market transaction.
These trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 23, 2025. Following the sale, she directly holds 29,375 Ordinary Shares, reflecting a relatively modest reduction in her equity position.
Compugen Ltd SVP of Business Development Zurit Levine exercised stock options and sold shares in a planned transaction. On April 10, 2026, she exercised options for 3,125 Ordinary Shares at exercise prices of $0.8292 and $1.15, then sold 3,125 Ordinary Shares at a weighted average price of $2.564 pursuant to a Rule 10b5-1 trading plan. Following these transactions, she directly holds 29,375 Ordinary Shares.
Ophir Eran submitted a Form 144 notice to sell 5,000 Ordinary shares of the issuer tied to an Employee Stock Option Plan, with the filing date shown as 04/14/2026. The record shows prior sales of 5,626 Ordinary shares on 04/01/2026 with an amount listed as 12412.68.